Catalyst

Slingshot members are tracking this event:

Theravance Biopharma (TBPH) announces new development partner, Celgene (CELG), for its multivalent NS5A inhibitor TD-6450

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
CELG

100%
TBPH

100%

Additional Information

Additional Relevant Details the author of this article is long on TBPH
http://seekingalpha....
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 28, 2015
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Td-6450, Hepatitis C, Phase 2a, Phase 2 Clinical Trial, Co-develop, Partnership